We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
EntreMed has commenced Phase Ib clinical trials to evaluate the pharmacokinetic
properties and safety of Panzem NCD, its next generation formulation of its
lead product candidate, Panzem (2-methoxyestradiol or 2ME2).
Keryx Biopharmaceuticals has announced that the Collaborative Study Group has
recommended the company proceed to the Phase III portion of its Phase II/III
clinical program of KRX-101 for the treatment of diabetic nephropathy, as planned.
Targeted Genetics and Celladon have announced a collaboration agreement to develop
adeno associated virus (AAV)-based gene therapies for the treatment of congestive
heart failure (CHF).
BioDelivery Sciences International has announced that, in laboratory testing,
it recently applied its licensed and patented Bioral "nanocochleate"
drug delivery technology to aspirin and traditional non-steroidal anti-inflammatory
drugs (NSAIDs) that are not selective Cox-2 inhibitors.
High body mass index (BMI) is associated with an increased risk of oral contraceptive
(OC) failure, according to the results of a case-control study published in
the January issue of Obstetrics & Gynecology.
Alnylam Pharmaceuticals, a leading RNAi therapeutics company, has initiated
a therapeutic development program for the treatment of respiratory syncytial
virus (RSV) infection.
Theravance has enrolled the first subjects in a Phase I clinical study designed
to assess the safety, tolerability and pharmacokinetics of its investigational
gastrointestinal (GI) prokinetic, TD-2749.
Prana Biotechnology has received a clinical trials authorization from the Medicines
and Healthcare Products Regulatory Agency of the UK to initiate the potentially
pivotal PLACQUE (Progression Limitation in Alzheimer's: ClioQUinol's Efficacy)
Phase II/III clinical trial.